-
Je něco špatně v tomto záznamu ?
Effect of Oxime Encapsulation on Acetylcholinesterase Reactivation: Pharmacokinetic Study of the Asoxime-Cucurbit[7]uril Complex in Mice Using Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry
R. Andrýs, A. Klusoňová, M. Lísa, J. Kassa, JŽ. Karasová
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- acetylcholinesterasa metabolismus MeSH
- cholinesterasové inhibitory aplikace a dávkování toxicita MeSH
- enzymatické testy MeSH
- hematoencefalická bariéra metabolismus MeSH
- hmotnostní spektrometrie MeSH
- hydrofobní a hydrofilní interakce MeSH
- imidazoly chemie MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- myši MeSH
- nosiče léků chemie MeSH
- otrava organofosfáty farmakoterapie MeSH
- oximy aplikace a dávkování farmakokinetika MeSH
- plocha pod křivkou MeSH
- přemostěné cyklické sloučeniny chemie MeSH
- pyridinové sloučeniny aplikace a dávkování farmakokinetika MeSH
- reaktivátory cholinesterázy aplikace a dávkování farmakokinetika MeSH
- sarin aplikace a dávkování toxicita MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Oxime-based molecules are used for the treatment of patients to reactivate acetylcholinesterase (AChE) function after organophosphate intoxication. However, their efficacy is limited by low penetration through the blood-brain barrier and fast elimination. In this work, the cucurbit[7]uril (CB[7]) carrier was used for the encapsulation of the clinical agent asoxime to enhance brain bioavailability and the treatment window. We present a pharmacokinetic study of asoxime and the asoxime-CB[7] complex in an in vivo mouse model. Ultrahigh-performance liquid chromatography with electrospray ionization-mass spectrometry detection was developed to determine asoxime and CB[7] in biological fluids and tissues after thorough optimization of chromatographic conditions. The dihydroxypropane-silica stationary phase using hydrophilic interaction liquid chromatography conditions provided the best chromatographic performance. The final method was validated and applied for the pharmacokinetic study of mouse plasma, urine, bile, liver, kidney, and brain samples at different times after administration of asoxime and the asoxime-CB[7] complex. The results showed a greater than 3-fold increase in the area under the curve (AUC) in the brain for asoxime administered as a complex with CB[7] relative to that for the administration of asoxime alone. The effectiveness of the treatment strategy was evaluated using a reactivation study and a functional observatory battery. Protection of brain AChE activity is crucial for saving human lives or reducing the consequences of poisoning. The asoxime administered as a complex increased the brain activity by approximately 30% compared to that with atropine alone. CB[7] coadministration improved the AChE activity by 11%, which agrees with the higher asoxime AUC assessed in the pharmacokinetic study.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004226
- 003
- CZ-PrNML
- 005
- 20220127145425.0
- 007
- ta
- 008
- 220113s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.1c00257 $2 doi
- 035 __
- $a (PubMed)34019427
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Andrýs, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic
- 245 10
- $a Effect of Oxime Encapsulation on Acetylcholinesterase Reactivation: Pharmacokinetic Study of the Asoxime-Cucurbit[7]uril Complex in Mice Using Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry / $c R. Andrýs, A. Klusoňová, M. Lísa, J. Kassa, JŽ. Karasová
- 520 9_
- $a Oxime-based molecules are used for the treatment of patients to reactivate acetylcholinesterase (AChE) function after organophosphate intoxication. However, their efficacy is limited by low penetration through the blood-brain barrier and fast elimination. In this work, the cucurbit[7]uril (CB[7]) carrier was used for the encapsulation of the clinical agent asoxime to enhance brain bioavailability and the treatment window. We present a pharmacokinetic study of asoxime and the asoxime-CB[7] complex in an in vivo mouse model. Ultrahigh-performance liquid chromatography with electrospray ionization-mass spectrometry detection was developed to determine asoxime and CB[7] in biological fluids and tissues after thorough optimization of chromatographic conditions. The dihydroxypropane-silica stationary phase using hydrophilic interaction liquid chromatography conditions provided the best chromatographic performance. The final method was validated and applied for the pharmacokinetic study of mouse plasma, urine, bile, liver, kidney, and brain samples at different times after administration of asoxime and the asoxime-CB[7] complex. The results showed a greater than 3-fold increase in the area under the curve (AUC) in the brain for asoxime administered as a complex with CB[7] relative to that for the administration of asoxime alone. The effectiveness of the treatment strategy was evaluated using a reactivation study and a functional observatory battery. Protection of brain AChE activity is crucial for saving human lives or reducing the consequences of poisoning. The asoxime administered as a complex increased the brain activity by approximately 30% compared to that with atropine alone. CB[7] coadministration improved the AChE activity by 11%, which agrees with the higher asoxime AUC assessed in the pharmacokinetic study.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a plocha pod křivkou $7 D019540
- 650 _2
- $a hematoencefalická bariéra $x metabolismus $7 D001812
- 650 _2
- $a přemostěné cyklické sloučeniny $x chemie $7 D001952
- 650 _2
- $a cholinesterasové inhibitory $x aplikace a dávkování $x toxicita $7 D002800
- 650 _2
- $a reaktivátory cholinesterázy $x aplikace a dávkování $x farmakokinetika $7 D002801
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a enzymatické testy $7 D057075
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a imidazoly $x chemie $7 D007093
- 650 _2
- $a hmotnostní spektrometrie $7 D013058
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a otrava organofosfáty $x farmakoterapie $7 D062025
- 650 _2
- $a oximy $x aplikace a dávkování $x farmakokinetika $7 D010091
- 650 _2
- $a pyridinové sloučeniny $x aplikace a dávkování $x farmakokinetika $7 D011726
- 650 _2
- $a sarin $x aplikace a dávkování $x toxicita $7 D012524
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Klusoňová, Aneta $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic
- 700 1_
- $a Lísa, Miroslav $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003 Hradec Králové, Czech Republic
- 700 1_
- $a Kassa, Jiří $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences Hradec Králové, University of Defence, Tychonova 1, 160 00 Praha, Czech Republic
- 700 1_
- $a Karasová, Jana Žd'árová $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences Hradec Králové, University of Defence, Tychonova 1, 160 00 Praha, Czech Republic
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 18, č. 6 (2021), s. 2416-2427
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34019427 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145422 $b ABA008
- 999 __
- $a ok $b bmc $g 1751627 $s 1155375
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 18 $c 6 $d 2416-2427 $e 20210521 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20220113